Partnership27 Mar 2024, 01:01 am
Sanofi India and Cipla Announce Exclusive Partnership for Distribution of Central Nervous System Products
AI Summary
Sanofi India Limited (SIL) and Cipla Limited have entered into an exclusive agreement for the distribution and promotion of SIL's Central Nervous System (CNS) products in India for an initial period of five years. Cipla will leverage its marketing and sales capabilities and network to expand access to these treatments for patients. SIL will continue to own, import, and manufacture its CNS products.
Key Highlights
- Sanofi India and Cipla announce an exclusive partnership for distribution and promotion of SIL’s CNS products in India
- Cipla will be responsible for distribution, while SIL will continue to own, import, and manufacture
- Cipla will leverage its capabilities and network to expand access to these treatments for patients